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Abstract
Given considerable variation in diagnostic and therapeutic practice, there is a need for national guidance on the use of
neuroimaging, fluid biomarkers, cognitive testing, follow-up and diagnostic terminology in mild cognitive impairment (MCI).
MCI is a heterogenous clinical syndrome reflecting a change in cognitive function and deficits on neuropsychological testing
but relatively intact activities of daily living. MCI is a risk state for further cognitive and functional decline with 5–15%
of people developing dementia per year. However, ∼50% remain stable at 5 years and in a minority, symptoms resolve
over time. There is considerable debate about whether MCI is a useful clinical diagnosis, or whether the use of the term
prevents proper inquiry (by history, examination and investigations) into underlying causes of cognitive symptoms, which can
include prodromal neurodegenerative disease, other physical or psychiatric illness, or combinations thereof. Cognitive testing,
neuroimaging and fluid biomarkers can improve the sensitivity and specificity of aetiological diagnosis, with growing evidence
that these may also help guide prognosis. Diagnostic criteria allow for a diagnosis of Alzheimer’s disease to be made where MCI
is accompanied by appropriate biomarker changes, but in practice, such biomarkers are not available in routine clinical practice
in the UK. This would change if disease-modifying therapies became available and required a definitive diagnosis but would
present major challenges to the National Health Service and similar health systems. Significantly increased investment would
be required in training, infrastructure and provision of fluid biomarkers and neuroimaging. Statistical techniques combining
markers may provide greater sensitivity and specificity than any single disease marker but their practical usefulness will depend
on large-scale studies to ensure ecological validity and that multiple measures, e.g. both cognitive tests and biomarkers, are
widely available for clinical use. To perform such large studies, we must increase research participation amongst those with
MCI.
Keywords: mild cognitive impairment, dementia, biomarkers, amyloid, tau, CSF, clinical trials, risk reduction, cerebrovascular,
neurodegeneration, Alzheimer’s, Lewy body, neuropsychology, neuroimaging, older people
Background
In November 2019, four of the authors (JS, DA, JOB and
AB) convened a consensus meeting of researchers, clinicians
and other stakeholders in Manchester, UK. The objective was
to consider the evidence base for the clinical and heuristic
utility of the mild cognitive impairment (MCI) concept and
provide a roadmap for future clinical practice and transla-
tional research across the UK. During the one-day seminar,
we attempted to describe the scope of use of MCI as a
diagnostic category, determine its utility and explore the
implications of its continued use in research and clinical
practice. There have been previous attempts to generate
consensus on the utility of the term ‘Mild Cognitive Impair-
ment’ [1], and there is some agreement that defining an at-
risk cognitive state may usefully describe patient cohorts at
a population level. However, only 5–15% of people with
MCI progress to dementia every year. Therefore, in the
absence of treatments to slow or halt neurodegeneration,
the heterogeneity of the syndrome and the variability of the
ensuing trajectory create uncertainty about whether a diag-
nosis of MCI per se is helpful or harmful for the individual. A
‘diagnosis’ of MCI may present an opportunity for vascular
risk reduction and behavioural change in some people, but
without clear communication of prognosis might also lead to
illness behaviour or increased healthcare utilisation and carer
stress. In this paper, we aim to create a tractable problem
statement as a framework for future national guidance on
minimum standards in diagnosis and management of MCI.
Diagnostic criteria
MCI is defined as objective cognitive impairment on neu-
rocognitive testing in the absence of significant impairment
of instrumental activities of daily living(ADL) [2]. This
cognitive state is not always accompanied by a subjective
awareness of cognitive impairment, so collateral history is
important. Conversely, a subjective awareness of cognitive
impairment is not always accompanied by objective evidence
of either a personal trajectory of cognitive or functional
decline or lower than normal cognitive functioning for age, a
state somewhat controversially labelled ‘subjective cognitive
decline’ [3].
The definition of MCI in an individual or a cohort
depends on which cognitive tests are used and the determina-
tion of ‘impairment’ in instrumental ADLs. The presence or
absence of MCI is therefore dependent on the sensitivity and
specificity of the tests used, population norms and estimates
of premorbid cognitive functioning. Without clear collateral
history, decline in an individual’s cognitive functioning may
be inferred from previous peak occupational or educational
attainment [4, 5]. Where doubt remains, two tests separated
in time may be required. Using normative neuropsycholog-
ical criteria, e.g. performance 1.5 standard deviations (SD)
lower than the population mean, relies on the availability
of comprehensive cognitive testing and well-developed age-
and education-adjusted population norms [6]. Using a 1.5
SD cut-off is more sensitive to decline than a 2-SD cut-
off [7], but necessarily less specific. In addition, any such
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cut-off is arbitrary, and there will be individuals (7% at the
1.5 SD cut-off) who score and have always scored lower
than their age-matched peers. Many of these people have
stable, normal cognitive function, but may come to medical
attention due to age-associated comorbidity, depression or
other disorders. Similarly, those with premorbid high cogni-
tive scores have further to decline before reaching the cut-
point for impairment and may sometimes be labelled with
‘subjective cognitive impairment’ before MCI.
Diagnostic criteria for ‘MCI’ have developed over many
decades and international consensus criteria have been devel-
oped [2, 8–11]. We now know that neurodegenerative dis-
eases develop many years before symptoms are observed.
When applied to cognitively normal populations, imaging
and fluid biomarkers of pathological changes underpinning
Alzheimer’s disease and other common causes of dementia
has led to the definition of prodromal (MCI) and pre-
clinical stages [12]. Age remains the biggest risk factor for
the development of cognitive impairment but many other
factors including socioeconomic status, genetics, education,
environmental exposure and other comorbidities, e.g. mid-
life cardiovascular risk, are associated with worse later-life
cognitive function [13–15].
Prevalence and incidence of MCI
The incidence and prevalence rates of MCI are heteroge-
neous across studies due to variation in definitions and
diagnostic criteria. The COSMIC collaboration [8] found an
MCI prevalence of 6% in those over 60 years of age across 11
studies, and the updated American Academy of Neurology
guideline estimated 6.7% prevalence in 65–69 year olds and
25% for ages 80–84 [16]. A recent meta-analysis estimated
22.5 new cases per 1000 person-years in the 75–79 age
group and 60/1000 person-years in the over 85s [17], noting
significant heterogeneity in cohort definitions and cognitive
measures. There is widespread variation in the rates of MCI
diagnosis across UK memory services. Some rarely if ever
diagnose the condition, whereas other services’ rates may be
20% or more [18].
Aetiology
MCI is defined as a syndrome, agnostic of aetiology, so
its underlying causes are heterogeneous. Importantly, not
everyone with MCI has a neurodegenerative disease. Nei-
ther does every individual have a single underlying cause
for their cognitive impairment. Clinical identification of
prodromes of Alzheimer, Lewy body, vascular and fron-
totemporal dementias (FTD) is important, but not always
possible, partly because as age increases, overlapping neu-
ropathological processes are the rule [19]. In older peo-
ple, significant physical comorbidity can create complex
interactions between cognitive impairment and frailty. In
those with major mental health problems like depressive ill-
ness, cognitive impairment can be a prominent component,
potentially masking or acting synergistically with underlying
neurodegeneration. Sometimes, such states form the part of
a spectrum of disorders with variably overlapping: health
anxiety, cognitive sequelae of psychiatric illness (particularly
depressive symptoms) and functional neurological disorders.
This spectrum, commonly defined as ‘Functional Cognitive
Disorder’ is associated with significant subjective distress,
which may not be relieved by negative investigation results
[20]. This heterogeneity of aetiologies between and within
individuals with cognitive impairment creates wide variation
in diagnosis, prognosis and therapeutic approach. With-
out tissue-based diagnosis, clinico-pathological correlation
is exceptionally poor, both in leading centres and routine
practice [21], also in UK routine practice [9].
Research diagnostic criteria
Reducing phenotypic heterogeneity in interventional stud-
ies increases statistical power and consistent definition of
MCI may prevent inappropriate exposure to experimental
medicines [22,23]. In observational studies, strict criteria
reduce confounding, improving the validity of findings. It is
common for diagnostic criteria to start in a research setting
and then to move into the clinic over time beginning with
tertiary/specialist clinics; criteria commonly also develop
over time. One example is the evolution of the MCI concept
from a purely amnestic syndrome to include non-amnestic
impairments and from single domain complaints to multi-
domain impairment, which may have implications both for
the underlying pathology and risk of progression. Similarly,
the use of biomarkers has begun to transition from research
to clinical practice, initially led by structural imaging to
exclude alternative pathologies and latterly to provide pos-
itive evidence for neurodegeneration or cerebrovascular dis-
ease. More recently, molecular markers for specific patholo-
gies have become available [2, 24, 25]. The US Food and
Drug Administration has recently issued draft guidance on
the use of biomarkers for clinical trial recruitment. The move
from research to clinical use must be evaluated in terms of
its utility to the patient, especially in the absence of disease-
modifying treatments. The earnest pursuit of population
‘homogeneity’, vital to some research efforts, needs to be
moderated in the clinic with an appreciation of individual
patients’ complexity, comorbidity and individual wishes and
the relative cost–benefit for the individual and the wider
healthcare system of procedures and testing.
The course of MCI
In keeping with aetiological heterogeneity, rates of progres-
sion in MCI are variable. In studies lasting over 5 years,
annual rates of progression to dementia have been estimated
at between 8 and 15% [26], but there is considerable varia-
tion (16% in the Alzheimer’s Disease Neuroimaging Initia-
tive cohort). Factors predicting faster progression are shown
in Box 1. In UK clinical practice, the duration of follow-up
is a source of considerable practice variation (Box 2). Many
memory clinics will discharge patients with MCI diagnoses
to primary care until and unless they deteriorate, despite the
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National Institute for Health and Care Excellence (NICE)’s
2006 Dementia Guideline recommending annual follow-up
(the advice in section 1.3.3.3 arguably still relevant as the
2018 guidance did not include MCI [27,28]). Other practice
guidelines also recommend follow-up on an annual basis
[16]. Rarely, memory services follow the course of cognitive
impairment until the threshold for dementia is reached, or
no further deterioration is expected. Full implementation of
a policy of annual follow-up would have enormous implica-
tions for services in acute and mental health trusts across the
UK, necessitating significant investment.
Box 1 Factors predicting more rapid progres-
sion to dementia
1. Amnestic subtype [80, 81]
2. Multidomain impairment [82]
3. Worse cognitive impairment [80]
4. Significant cerebral WMH [83]
5. APOE4 carrier status
6. Abnormal brain AB1–42 on PET or CSF analysis
7. Abnormal tau on PET or CSF analysis
8. Significant atrophy
a. Focal hippocampal (MTA score)
b. Global cerebral atrophy/ventricular
enlargement out of keeping with age
9. Evidence of a personal trajectory of decline
10. Depression
11. Frailty
12. Delirium
13. Poor glycaemic control
Box 2 Potential sources of variability in MCI
diagnostic practice
• Referral pathways
• Specialist training
• Care setting
• Lack of NICE guidance on minimum diagnostic
standards
• Investigation availability
◦ Imaging
◦ CSF biomarkers
• Expertise availability
◦ Neuropsychology
◦ Dementia neuroradiology
• Implementation of diagnostic criteria [84]
Primary prevention
Prevention of the underlying causes of MCI is a major public
health challenge. The high numbers of people with dementia
and cognitive disorders and their economic impact mean
effective public health response is a priority [13]. Reducing
cardiovascular risk factors, treating depression, minimising
anticholinergic burden and treatment of comorbid con-
ditions including sensory impairments, all have a role in
improving cognitive health. Control of midlife hypertension,
smoking cessation and the promotion of social, physical
and intellectual activity should be priorities at national and
international levels [29]. World Health Organization guide-
lines currently recommend a Mediterranean diet, reductions
in alcohol and targeting obesity amongst other individual
interventions with variable levels of evidence [30].
Secondary prevention and management
Patients and the public should be informed about the
opportunities for risk reduction. Multidomain interventions
including diet and lifestyle alongside cognitive training have
demonstrated some effectiveness [31, 32]. Their translation
into routine clinical practice would require a significant
investment in cognitive health that is currently not evident
in, e.g. the National Health Service (NHS) long-term plan.
Those with more severe or multidomain impairment who
are at the greatest risk of progression may benefit from
more frequent follow-up, with the opportunity to combine
cognitive and physical health checks in primary care as
routine. This setting may also offer the opportunity to
address sensory deficits and other remediable risk factors
for progression.
Acetylcholinesterase inhibitors (AChEIs) have been
shown to be ineffective in the management of ‘all cause’
MCI as clinically defined, and although they are cheap
and generally well tolerated, may cause gastrointestinal and
cardiac side effects [33]. It is possible that some biomarker-
defined subgroups might benefit more from AChEIs or
Memantine, but this requires further study. The advent
of disease-modifying medications would offer a chance to
address underlying primary neurodegenerative pathologies,
turning Alzheimer, Lewy body and frontotemporal lobar
degeneration into chronic cognitive conditions to be
managed in the context of comorbidities. However, these
conditions will probably only be treatable if diagnosed using
molecular methods at an early stage.
The role of cognitive testing
The level of specialist knowledge and experience required to
administer and interpret many neuropsychological tests is
high, which can limit patient access. Simpler, bedside screen-
ing tests like the mini-mental state examination (MMSE)
[34] and montreal cognitive examination (MoCA) [35] have
utility but may exhibit ceiling effects in those with the
mildest levels of impairment or high pre-morbid cognitive
function. More detailed and sensitive tests may help in
early detection but are not always available, and a personal
trajectory of decline based on repeated testing may be most
sensitive in patients who at baseline differ from the pop-
ulation mean. The boundary between MCI and subjective
cognitive impairment is complex and necessarily arbitrary
in some cases, depending on a complex interaction between
the properties of the test used including ceiling effects and
the patient’s educational attainment, language and cultural
factors. Population-normed tests may produce false-negative
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results in those with premorbid functioning well above the
mean, and false-positives in those with premorbid scores
below the population mean, requiring tools to accurately
assess premorbid function [36].
Some modern cognitive tests take the advantage of
computerised interfaces and continuous testing at higher
temporal resolution [37–39]. These may combine testing
modalities and examine multiple neurocognitive domains
[40], or focus on single, purportedly highly sensitive domains
[37]. The increasing use of computer and smartphone
technology in older populations means that there is
potential for population norms to be developed with
less research effort and expense than traditional methods
while accounting for test–retest variability [41]. The aim
of computerised testing goes beyond the measurement of
trajectories and sensitive subtyping of neurodegenerative
diseases [41]. Continuous monitoring may also offer
simple measurements of functional status, beyond lists of
ADLs, and more sensitively detect functional decline [42].
Computerised testing also invites telemedical applications,
providing opportunities for early detection and diagnosis,
for triaging those with subjective impairments, and in the
era of the severe acute respiratory syndrome coronavirus 2
pandemic may allow at least some assessment of cognitive
function while maintaining physical distancing measures.
However, moving too rapidly to web-based healthcare risks
exacerbating health inequalities. In the UK, internet use
is markedly lower in the over-65 age group and lower still
in those from ethnic minority backgrounds over 65 [43].
However, since 2011, this age group has seen the largest
increase in recent internet use [44].
Structural neuroimaging
The use of structural neuroimaging in the assessment of MCI
in the UK is highly variable. Many clinicians requesting
neuroimaging do not have access to the images themselves,
relying only on written reports. Computed tomography is
often used instead of magnetic resonance imaging (MRI)
to ‘rule out’ structural causes of cognitive decline, although
these are relatively rare. However, this may be because MRI
is more costly, not commissioned or not available. The UK
has the 2nd lowest number of MRI scanners per capita
in the European Union (7.2/million) [45], of which 29%
are at least 10 years old. Similarly, the UK has only 232
radiologists describing neuroimaging as a ‘primary specialist
interest’ [46] of whom a minority are specialists in neurode-
generation. This suggests a need and opportunity for training
and development of neuroradiologists, and decision-support
tools trained on the large quantities of structural neuroimag-
ing data acquired every year, which would require national
harmonisation efforts. Although age-standardised norms are
now available for volumetric analysis of hippocampal struc-
tures for the UK population, such analyses are little used
clinically [47].
All diagnostic criteria for the major causes of dementia
contain guidance on the use of MRI neuroimaging [48–51].
NICE currently recommends structural neuroimaging for
subtyping in ‘suspected early dementia’. However, although
MCI represents a state of ‘suspected early dementia’, no
further guidance is given on selection of appropriate struc-
tural imaging. Imaging should not replace a detailed clinical
assessment, but can give insights into the presence, absence
or degree of neuronal injury. MRI is also a sensitive indi-
cator of cerebrovascular disease. The severity of white matter
hyperintensities (WMH) may represent underlying ischemia
and impact upon the course of cognitive symptoms [52].
Cerebrovascular disease is associated with a typical pattern of
cognitive slowing and executive dysfunction with neuropsy-
chiatric symptoms also affecting broader functioning like
depression and apathy [53, 54]. However, relying on MRI
images to provide a single attributable cause for complex
cognitive and emotional changes is likely to over-emphasise
the importance of age-related and often stable WMH, so
integration with the clinical and neuropsychological picture
is vital.
Nuclear imaging
Nuclear imaging is recommended by NICE for early demen-
tia when the ‘diagnosis is uncertain and Alzheimer’s Dis-
ease (AD) is suspected’. For suspected AD and FTD, fluo-
rodeoxyglucose positron emission tomography (FDG-PET)
or single positron emission computed tomography (SPECT)
scanning is recommended depending on availability; for
suspected Dementia with Lewy Bodies (DLB), dopamine
SPECT (or myocardial metaiodobenzylguanidine scintigra-
phy if not available) is suggested. Availability across the UK
is, however, patchy; there are currently only 62 UK PET
scanners, located usually in University teaching hospitals or
research centres [55].
The 2018 NICE diagnostic guidance was limited to
‘suspected dementia’ and does not recommend amyloid-
sensitive PET-imaging. However, appropriate use criteria
for amyloid PET imaging include ‘Unexplained MCI’ [56]
(Box 3). Since the evidence-based review for the 2018
NICE guidelines, several large-scale clinical studies have
been published, which have consistently demonstrated the
utility of PET in diagnosis and management. The Imaging
Dementia-Evidence for Amyloid Scanning (IDEAS) study
demonstrated changes in patient management in 60% of
those with MCI after amyloid-PET although this was mostly
driven by increased prescription of AChEIs to patients with
a positive scan (an unlicensed indication in the UK); 24%
of MCI patients received a change in ‘counselling about
safety and future planning’ [57]. Emerging evidence suggests
that accurate and timely diagnosis is beneficial even in the
absence of disease-modifying therapies [58], but molecular
diagnosis may also be a rate limiting factor in accessing novel
disease-modifying medication. However, the evidence of
clinical benefit, infrastructure and funding lag behind. Both
clinical scanning time and relevant radiotracer manufacture
in the UK is extremely limited. The potential impact of
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PET-amyloid is the subject of ongoing health-economic
research.
Box 3 Appropriate use criteria for amyloid-
PET, used [with permission] from Johnson et al.
[56]
Amyloid imaging is appropriate in the situations listed
here for individuals with all of the following char-
acteristics: (i) a cognitive complaint with objectively
confirmed impairment; (ii) AD as a possible diagnosis,
but when the diagnosis is uncertain after a compre-
hensive evaluation by a dementia expert and (iii) when
knowledge of the presence or absence of Aβ pathology
is expected to increase diagnostic certainty and alter
management.
1. Patients with persistent or progressive unex-
plained MCI
2. Patients satisfying core clinical criteria for pos-
sible AD because of unclear clinical presentation, either
an atypical clinical course or an etiologically mixed
presentation
3. Patients with progressive dementia and atypi-
cally early age of onset (usually defined as 65 years or
less in age)
Amyloid imaging is inappropriate in the follow-
ing situations
4. Patients with core clinical criteria for probable
AD with typical age of onset
5. To determine dementia severity
6. Based solely on a positive family history of
dementia or presence of apolipoprotein E (APOE)ε4
7. Patients with a cognitive complaint that is
unconfirmed on clinical examination
8. In lieu of genotyping for suspected autosomal
mutation carriers
9. In asymptomatic individuals
10. Nonmedical use (e.g. legal, insurance coverage
or employment screening)
The role of fluid biomarkers:
The development of blood and cerebrospinal fluid (CSF)-
based biomarkers could offset the significant capital
investment the UK would need to expand PET diagnostic
infrastructure and training to ensure access. Molecular
biomarkers: phosphorylated tau, total tau, Aβ1–42 and
perhaps neurofilament light (NFL) may offer a better
combination of sensitivity and specificity than single-tracer
nuclear studies, especially in older populations. However,
this would depend on greater acceptance and availability of
lumbar puncture in memory-clinic settings.
CSF biomarker testing has been increasingly used in
research for over 15 years, with meta-analyses supporting
its use to identify AD pathology in the context of MCI
[59]. Similarly to imaging, this has moved from being used
to exclude infectious or inflammatory processes towards
providing positive evidence for underlying AD pathology.
CSF analysis for phosphorylated tau and Aβ1–42 (or
Aβ1–42/Aβ1–40 ratio)—whose measurement is increasingly
being standardised and automated [56, 60–63] are currently
recommended (alongside FDG-PET) in the UK by NICE
for the diagnosis of Alzheimer disease in those with
suspected neurodegeneration if uncertainty remains after
clinical assessment and structural imaging [64]. However,
notwithstanding the advice to use in ‘suspected early
dementia’, there is no concomitant guidance for use in MCI
specifically, although current diagnostic criteria allow for a
diagnosis of AD to be made at the MCI stage in the presence
of AD biomarkers. CSF examination is rarely performed as
part of the diagnostic work-up in the UK in contrast to many
European centres [65], although it is safe, well tolerated [66]
and cheaper than PET imaging.
In recent years there have been major advances in the
development of blood-based biomarkers for AD (plasma Aβ
and p-tau) and for all-cause neurodegeneration (serum NFL)
[67, 68]. Clinical development and roll out of these measures
would have major impacts on the molecular diagnosis of
early neurodegeneration.
However, it will be necessary to develop age-specific
norms and validate the sensitivity and specificity of both
plasma and CSF biomarkers in representative samples
including older people (including those with multiple
pathologies, or age-related amyloidosis) and those with
depression and severe enduring mental illness.
Measuring diagnostic test performance entails value
judgements about the cost of false-positives and false-
negatives (the loss-function) [69]. In the absence of a
disease-modifying medication, false-positive diagnoses may
have greater impact on the patient than false-negatives.
In the presence of an expensive disease modifier, there
would be commensurate health and economic concerns of
false-positive diagnosis. However, false-negative diagnoses
might then represent missed opportunities for intervention
before irreversible neuronal injury occurs. The impetus
to use available molecular tests in MCI is strong, but
concerns remain around their cost-utility. Health economic
analyses are underway to examine patient and health-
system cost-benefit [67]. Early evidence suggests identifying
and reassuring people at lowest risk of progression (i.e.
biomarker negative patients) may provide the greatest health
economic benefit [70–72], and 74% of the general public
indicate they would wish to know if they had Alzheimer’s
before any symptoms develop [73, 74]. Although qualitative
interviews demonstrate that some with established cognitive
impairment do not wish to know their prognosis, these
people tend to be older, or managing other comorbidities
[75]. Despite the ‘mild’ moniker, an MCI diagnosis can
profoundly impact the individual and their perceived daily
functioning, as well as family members and relationships.
So, research on MCI should include not only measures
of economic and healthcare utilisation, but also examine
the psychosocial impact of investigation and diagnosis on
patients and carers.
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Clinical benefits of accurate diagnosis may include the
resolution of uncertainty for patient and clinician, discharge
from regular clinic visits, referral to more appropriate special-
ties, advance care planning, access to clinical trials, advice on
current and future treatments, and counselling, support and
education.
Research participation
Patients should be offered research participation as a routine
part of clinical care. In some settings, this may mean
merely data collection. In others, clinical trials may be an
option. National infrastructure like the ‘Join Dementia
Research’ register should be routinely offered, in addition
to information about participation in immediately locally
available studies (https://www.joindementiaresearch.nihr.a
c.uk/). Engagement in research will always be the subject of
shared decision-making between practitioner and patient;
however, research activity may be associated with better
outcomes at individual and organisational levels [76, 77].
Many studies of putative disease-modifying therapies and
all studies of AChEs in MCI presumed due to AD were
performed before the advent of molecular biomarkers or
did not mandate them as inclusion criteria. This means that
some interventional studies, including major Phase 3 trials
[23] will have included individuals not likely to develop
AD dementia, reducing their statistical power. It follows
that if a pivotal trial included biomarker-positivity as an
inclusion criterion, similar evidence of biomarker positivity
would be required for the drug to be used in clinical practice.
The research community increasingly recognises the need
for early detection and diagnosis in order to prepare for the
advent of disease modification [78, 79]. The importance of
homogeneity in clinical trial populations means that trial-
ready populations for disease modification are increasingly
likely to be drawn only from sites with the ability to perform
molecular diagnostics (please see Supplementary Data for
additional material and full reference list).
Recommendations
• There is currently no NICE guidance on MCI. This means
there is no guidance as to how a large proportion of
cases seen in UK cognitive and memory clinics should
be investigated and managed. This leads to wide variation
in clinical practice and hinders optimal management of
these patients. NICE guidelines for the investigation and
follow-up of the MCI syndrome are urgently required.
• MCI should be considered a clinical syndrome with het-
erogeneous underlying pathologies and not a diagnosis
in its own right. Clinicians should attempt to provide
patients with an explanation for their decline in cognition,
which in some cases will include using biomarkers for the
early detection of neurodegeneration.
• Over-investigation of people with subjective cognitive
problems but little objective evidence of cognitive decline
may exacerbate health anxieties where present.
• For patients falling within the rubric of MCI, it is impor-
tant to identify and treat potentially modifiable contri-
butions to their cognitive dysfunction including but not
limited to the treatment of physical illness, depression
and other psychiatric disorders, isolation, optimisation
of hearing and visual disturbance, recommendations and
interventions to promote alcohol cessation, and rationali-
sation of medications (e.g. anticholinergics, hypnotics and
opiates).
• Given the heterogeneity of MCI, decisions about whom to
investigate and the depth of that investigation, including
the utility of molecular biomarkers, should be made on an
individual basis. However, as for patients with dementia,
blood screening is recommended, and patients with objec-
tive cognitive decline are likely to be offered structural
imaging.
• Patients with MCI should have equitable access to neu-
ropsychological testing and expertise.
• Procedures for implementing monitoring technologies of
cognition and functional deterioration in clinical practice
are required.
• NICE guidance for dementia supports the use of CSF
biomarkers in the diagnosis of Alzheimer’s disease. Given
the complexity of diagnosing patients with MCI and
emerging evidence that CSF can aid in prognostication,
CSF sampling may be useful on an individual by indi-
vidual basis in patients with MCI in whom a diagnosis
of Alzheimer’s disease is suspected. The NHS requires
evidence-based guidance on the use of biomarkers in mild
cognitive impairment, and this should form part of any
NICE guidance. The advent of disease-modifying thera-
pies for prodromal Alzheimer’s disease would mean that
significant investment in biomarker and neuroimaging
infrastructure would be necessary to ensure timely access
for NHS patients. This will require significant planning
and engagement with commissioners and providers.
• Patients with MCI should be offered review at least annu-
ally in either primary or secondary care.
• All patients with MCI should be offered access to research.
• Research on MCI should include not only measures of
economic and healthcare utilisation, but also examine the
psychosocial impact of being diagnosed with MCI on
patients and carers.
Supplementary Data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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